1. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases 
Hironori Uruga, MD, PhD, Emine Bozkurtlar, MD, Tiffany G. Huynh, BA, Alona Muzikansky, MA, Yasushi Goto, MD, PhD, Maria Gomez- Caraballo, BA, Aaron N. Hata, MD, PhD, Justin F. Gainor, MD, Eugene J. Mark, MD, Jeffrey A. Engelman, MD, PhD, Michael D. Lanuti, MD, Mari Mino-Kenudson, MD 
Journal of Thoracic Oncology 
Volume 12, Issue 3, Pages (March 2017)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
(A and B) An example of lung adenocarcinoma exhibiting membranous expression of programmed death ligand 1 on the vast majority of tumor cells. Original magnification, ×100 (A) and ×200 (B). (C and D) CD8-positive tumor-infiltrating lymphocytes are semiquantitatively evaluated on the tumor cells (arrow), in the interstitial stroma (arrow head) (C), and in the stroma at the tumor border (arrow) (D). Original magnification, ×100 (C and D).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Kaplan-Meier plot for the entire cohort (A) and the cohort treated with adjuvant therapy (B) stratified by programmed death ligand 1 (PD-L1) expression status with use of a 1% cutoff.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4. Supplementary Figure 1
A&B: An example of lung adenocarcinoma exhibiting PD-L1 expression in 1% of tumor cells. The PD-L1 expression on the tumor cells (arrows in B) is limited to the area immediately adjacent to inflammatory cells that also show PD-L1 expression (circle in B). Similar foci are seen in a scattered manner throughout the entire tumor in this case.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

5. Supplementary Figure 2
Correlation of PD-L1 expression between the primary tumor and N1 lymph node (A), between the primary tumor and N2 lymph node (B), and between N1 and N2 lymph nodes (C).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

6. Supplementary Figure 3
A&B: An example of lung adenocarcinoma in which the primary tumor (A) exhibits predominant papillary pattern and no PD-L1 expression, while metastatic deposits in the N1 lymph node (B) show solid pattern and PD-L1 expression on all tumor cells and surrounding histiocytes (A&B: x200). C&D: Another example of adenocarcinoma with predominant acinar pattern and PD-L1 expression on 5% of the tumor cells in both the primary tumor (C) and N1 lymph node (D) (C&D: x200).
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

7. Supplementary Figure 4
Kaplan-Meier plot for the entire cohort (A) and the cohort treated with adjuvant therapy (B) stratified by PD-L1 expression status with using 5% cut-off.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

8. Supplementary Figure 5
Kaplan-Meier plot for the entire cohort (A) and the cohort treated with adjuvant therapy (B) stratified by PD-L1 expression status with using 50% cut-off.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions